Glaucoma Therapeutics Market is expected to reach US$ 10 Bn by 2031

Fact.MR’s recent glaucoma therapeutics industry report concludes that the market will reach US$ 6.6 Bn by the end of 2021. Long-term forecast suggests a largely steady outlook, with an anticipated CAGR of 4.7% and a valuation of US$ 10 Bn by the end of the assessment period lasting from 2021-2031.

Historical market performance reveals that the industry registered modest growth, with a documented growth rate of 2.8% from 2016-2020. While significant disruptions were experienced with regard to glaucoma surgeries across the world during COVID-19, several developing regions, including India, experienced a noteworthy upsurge in emergency surgical procedures, expanding over 4x. More emphasis was provided to non-incisional surgical procedures to reduce the risk of viral load transmission.

It is expected that by 2040, nearly 80 million people will suffer from primary open angle glaucoma, according to several studies. Furthermore, the Centers for Disease Control & Prevention expects the number of active glaucoma cases to rise to over 6 million by 2050. Hence, numerous collaborative efforts in the form of clinical trials, research funding and drug development are being initiated, which will likely bode well for market growth in forthcoming years.

Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=4775

Glaucoma Therapeutics Market Scope:

A latest publication by Fact.MR on the global Lactoferr in evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the market.

The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the market.

The principal aim of the study is to present exclusive information about how the market will perform during the forecast period of 2021-2031.

Important indicators for the successful growth of the Glaucoma Therapeutics are presented in this comprehensive report, which include Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described in an exhaustive way in Fact.MR’s study.

This research study can support readers to know the demand for Glaucoma Therapeutics supplements, and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in Computer Aided Detection, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the market.

Insights and wisdom presented in this Fact.MR study can be leveraged by shareholders in the market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

In-depth Analysis on Competitive Landscape

Strategic collaborations enable manufacturers to increase production and meet consumer demand which will increase revenue and market share. New products and technologies will enable end-users to benefit from products that are eco-friendly by nature.

• In August 2021, Nova Eye Medical acquired glaucoma patents to expand its product line. With this acquisition Nova will expand and strengthen its portfolio of glaucoma surgical devices intellectual property, enabling the firm to introduce new products and to expand its indications in the future
• In May 2020, the U.S Food & Drug Administration approved Allergan Plc.’s DURYSTATM (bimatoprost implant) New Drug Application. The drug is amongst the first intracameral, sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma, or ocular hypertension

Get Customization on this Report for Specific Research Solutions:- https://www.factmr.com/connectus/sample?flag=RC&rep_id=4775

Report benefits & key questions answered

• Post covid consumer spending on Glaucoma Therapeutics: the report also highlights the change in the buying behavior of consumers and shifts in purchasing power, post covid-19. This information will assist the businesses to plan their production and marketing strategies.
• Glaucoma Therapeutics demand outlook: the market intelligence study reports highlights the factor propelling the demand for Computer Aided Detection. As per the study, the demand for Glaucoma Therapeutics will grow through 2031.
• Glaucoma Therapeutics historical volume analysis: Fact.MR survey report provides insights into the sales registered over the last forecast year 2016 to 2020 and create estimates regarding the sales performance for 2021-2031.
• Glaucoma Therapeutics consumption by demographics: the report provides consumption by demographics analysis to assist the market players in designing their expansion strategies on the basis of consumption pattern of the customers.

Glaucoma Therapeutics Segmentations:

• Drug Class

  • Prostaglandins
  • Beta Blockers
  • Alpha Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Medications
  • Cholinergic Medications

• End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

 For in-depth competitive analysis, Buy Now –  https://www.factmr.com/checkout/4775

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of fortune 1,000 companies trust us for making their most critical decisions. We have offices in us and dublin, whereas our global headquarter is in dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our usp is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com